1. Pleural Mesothelioma, Why Determining a Therapeutic Direction Was Challenging

Pleural mesothelioma, a malignancy arising in the membrane surrounding the lungs, is a formidable disease characterized by late detection and poor prognosis. Although immune checkpoint inhibition (ICI) therapy has recently been introduced, the challenge lies in the fact that this costly treatment is not effective for all patients. Because it is impossible to predict who will benefit, patients have had to endure the risk of adverse effects amid uncertain hope.

2. DNA Methylation: The ‘Four Signals’ Sent by the Genome

The research team performed high‑resolution DNA methylation profiling on samples from 91 patients. DNA methylation constitutes a chemical modification that does not alter the nucleotide sequence but modulates gene expression by turning genes on or off. The analysis revealed that patients segregated into four distinct methylation subtypes, each exhibiting markedly different responses to immune therapy.

3. Discovery of Subtype A: More Than Doubling of Survival Duration

Notably, patients classified as Subtype A displayed a robust and favorable response to immune checkpoint inhibitors. Their median overall survival was more than twice that of patients in the other subtypes. This finding indicates that DNA methylation status can serve as a functional biomarker that not only reflects genetic information but also predicts patient survival and guides optimal therapeutic selection.

4. Implications and Future Outlook

These results have the potential to fundamentally reshape the standard diagnostic workflow for pleural mesothelioma. If clinical kits that differentiate methylation subtypes become widely available, physicians will be able to devise personalized anticancer strategies before initiating therapy. This approach could reduce unnecessary treatment‑related toxicity and markedly improve cure rates, accelerating the advent of precision oncology.